Diagnostics Indication Use Discovery Assay Development Clinical In-Market EXO-OC LDT Ovarian Cancer Early detection, high risk EXO-OC IVD Ovarian Cancer Screening, average risk Therapeutics Indication Use Discovery Pre-Clinical Clinical Approval EEV-001 Breast Cancer CAR-Exosome therapy EEV-002 Lung Cancer CAR-Exosome therapy EEV-003 Ovarian Cancer CAR-Exosome therapy in vitro in vitro in vitro PRODUCT PORTFOLIO INOVIQ’s product portfolio includes commercial exosome isolation products and an adjunct bladder cancer test, a clinical-stage diagnostic for ovarian cancer screening, a preclinical CAR-exosome therapeutic for solid tumours, and other research programs. Our pipeline priorities are to advance our EXO-OC ovarian cancer test and CARexosome therapy for triple negative breast cancer towards technical, clinical and commercial milestones. INOVIQ pipeline products have the potential to deliver significant clinical and commercial benefits to patients, health systems and shareholders. Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 7 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3